S&P 500   3,877.72 (+1.75%)
DOW   31,522.24 (+1.91%)
QQQ   319.23 (+1.62%)
AAPL   125.08 (+3.15%)
MSFT   235.72 (+1.44%)
FB   259.06 (+0.56%)
GOOGL   2,040.24 (+0.91%)
TSLA   694.64 (+2.83%)
AMZN   3,110.40 (+0.56%)
NVDA   546.41 (-0.40%)
BABA   240.25 (+1.05%)
CGC   34.75 (+6.11%)
GE   13.26 (+5.74%)
MU   93.69 (+2.36%)
NIO   48.93 (+6.88%)
AMD   84.41 (-0.12%)
T   28.40 (+1.83%)
F   11.92 (+1.88%)
ACB   11.23 (+6.75%)
DIS   194.03 (+2.64%)
BA   226.27 (+6.73%)
NFLX   547.24 (+1.56%)
BAC   35.62 (+2.62%)
S&P 500   3,877.72 (+1.75%)
DOW   31,522.24 (+1.91%)
QQQ   319.23 (+1.62%)
AAPL   125.08 (+3.15%)
MSFT   235.72 (+1.44%)
FB   259.06 (+0.56%)
GOOGL   2,040.24 (+0.91%)
TSLA   694.64 (+2.83%)
AMZN   3,110.40 (+0.56%)
NVDA   546.41 (-0.40%)
BABA   240.25 (+1.05%)
CGC   34.75 (+6.11%)
GE   13.26 (+5.74%)
MU   93.69 (+2.36%)
NIO   48.93 (+6.88%)
AMD   84.41 (-0.12%)
T   28.40 (+1.83%)
F   11.92 (+1.88%)
ACB   11.23 (+6.75%)
DIS   194.03 (+2.64%)
BA   226.27 (+6.73%)
NFLX   547.24 (+1.56%)
BAC   35.62 (+2.62%)
S&P 500   3,877.72 (+1.75%)
DOW   31,522.24 (+1.91%)
QQQ   319.23 (+1.62%)
AAPL   125.08 (+3.15%)
MSFT   235.72 (+1.44%)
FB   259.06 (+0.56%)
GOOGL   2,040.24 (+0.91%)
TSLA   694.64 (+2.83%)
AMZN   3,110.40 (+0.56%)
NVDA   546.41 (-0.40%)
BABA   240.25 (+1.05%)
CGC   34.75 (+6.11%)
GE   13.26 (+5.74%)
MU   93.69 (+2.36%)
NIO   48.93 (+6.88%)
AMD   84.41 (-0.12%)
T   28.40 (+1.83%)
F   11.92 (+1.88%)
ACB   11.23 (+6.75%)
DIS   194.03 (+2.64%)
BA   226.27 (+6.73%)
NFLX   547.24 (+1.56%)
BAC   35.62 (+2.62%)
S&P 500   3,877.72 (+1.75%)
DOW   31,522.24 (+1.91%)
QQQ   319.23 (+1.62%)
AAPL   125.08 (+3.15%)
MSFT   235.72 (+1.44%)
FB   259.06 (+0.56%)
GOOGL   2,040.24 (+0.91%)
TSLA   694.64 (+2.83%)
AMZN   3,110.40 (+0.56%)
NVDA   546.41 (-0.40%)
BABA   240.25 (+1.05%)
CGC   34.75 (+6.11%)
GE   13.26 (+5.74%)
MU   93.69 (+2.36%)
NIO   48.93 (+6.88%)
AMD   84.41 (-0.12%)
T   28.40 (+1.83%)
F   11.92 (+1.88%)
ACB   11.23 (+6.75%)
DIS   194.03 (+2.64%)
BA   226.27 (+6.73%)
NFLX   547.24 (+1.56%)
BAC   35.62 (+2.62%)
Log in
NASDAQ:ZSAN

Zosano Pharma Stock Forecast, Price & News

$1.35
+0.07 (+5.47 %)
(As of 03/1/2021 10:04 AM ET)
Add
Compare
Today's Range
$1.28
Now: $1.35
$1.38
50-Day Range
$0.81
MA: $1.18
$1.99
52-Week Range
$0.33
Now: $1.35
$3.06
Volume33,278 shs
Average Volume15.96 million shs
Market Capitalization$92.59 million
P/E RatioN/A
Dividend YieldN/A
Beta2.98
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its intracutaneous microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Zosano Pharma logo

Headlines

Why an East Bay migraine patch maker sees hope ahead
February 22, 2021 |  bizjournals.com
Zosano Pharma (ZSAN) in Focus: Stock Moves 6.3% Higher
January 12, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZSAN
CUSIPN/A
Phone510-745-1200
Employees56
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.40 per share

Profitability

Net Income$-37,590,000.00

Miscellaneous

Market Cap$92.59 million
Next Earnings Date3/12/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.41 out of 5 stars

Medical Sector

561st out of 1,962 stocks

Pharmaceutical Preparations Industry

271st out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$1.35
+0.07 (+5.47 %)
(As of 03/1/2021 10:04 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZSAN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZSAN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions

Is Zosano Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Zosano Pharma stock.
View analyst ratings for Zosano Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Zosano Pharma?

Wall Street analysts have given Zosano Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zosano Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Zosano Pharma?

Zosano Pharma saw a increase in short interest in January. As of January 15th, there was short interest totaling 8,000,000 shares, an increase of 17.0% from the December 31st total of 6,840,000 shares. Based on an average trading volume of 6,750,000 shares, the short-interest ratio is currently 1.2 days.
View Zosano Pharma's Short Interest
.

When is Zosano Pharma's next earnings date?

Zosano Pharma is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Zosano Pharma
.

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Co. (NASDAQ:ZSAN) announced its quarterly earnings data on Wednesday, November, 18th. The biotechnology company reported ($0.11) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.02.
View Zosano Pharma's earnings history
.

How has Zosano Pharma's stock been impacted by COVID-19?

Zosano Pharma's stock was trading at $0.5662 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZSAN stock has increased by 138.4% and is now trading at $1.35.
View which stocks have been most impacted by COVID-19
.

When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?

Shares of Zosano Pharma reverse split on Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for ZSAN?

3 brokerages have issued 1-year price targets for Zosano Pharma's stock. Their forecasts range from $2.00 to $2.00. On average, they expect Zosano Pharma's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 48.1% from the stock's current price.
View analysts' price targets for Zosano Pharma
or view top-rated stocks among Wall Street analysts.

Who are Zosano Pharma's key executives?

Zosano Pharma's management team includes the following people:
  • Mr. Steven Lo, Pres, CEO & Director (Age 54, Pay $155.67k)
  • Dr. Donald J. Kellerman, VP of Clinical Devel. & Medical Affairs (Age 66, Pay $353k)
  • Ms. Christine Matthews, Chief Financial Officer (Age 53)
  • Ms. Hayley Lewis, Sr. VP of Operations (Age 45)
  • Jeffrey L. Quillen, Sec.

Who are some of Zosano Pharma's key competitors?

What other stocks do shareholders of Zosano Pharma own?

When did Zosano Pharma IPO?

(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.

What is Zosano Pharma's stock symbol?

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

Who are Zosano Pharma's major shareholders?

Zosano Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.29%) and GSA Capital Partners LLP (0.18%).
View institutional ownership trends for Zosano Pharma
.

Which institutional investors are buying Zosano Pharma stock?

ZSAN stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC, and GSA Capital Partners LLP.
View insider buying and selling activity for Zosano Pharma
or or view top insider-buying stocks.

How do I buy shares of Zosano Pharma?

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zosano Pharma's stock price today?

One share of ZSAN stock can currently be purchased for approximately $1.35.

How much money does Zosano Pharma make?

Zosano Pharma has a market capitalization of $92.59 million. The biotechnology company earns $-37,590,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does Zosano Pharma have?

Zosano Pharma employs 56 workers across the globe.

What is Zosano Pharma's official website?

The official website for Zosano Pharma is www.zosanopharma.com.

Where are Zosano Pharma's headquarters?

Zosano Pharma is headquartered at 34790 ARDENTECH COURT, FREMONT CA, 94555.

How can I contact Zosano Pharma?

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.